Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Trius Therapeutics
July 14, 2015
Interview – Dong-A shifts sights from Korea to the US
December 08, 2014
Merck snaps up Cubist in $9.5bn antibiotic play
October 07, 2014
Takeout of Durata shows antibiotics investment can pay dividends
May 07, 2014
Development-stage M&A premiums reward very patient investors
December 17, 2013
Cubist turns positive on good news from gram-negative antibiotic
July 31, 2013
Cubist right to inject caution into much-needed acquisition spree
March 26, 2013
For Trius the hard work is just beginning as filing looms
March 08, 2013
Event – Trius hopes tedizolid success is infectious
January 16, 2012
IPO hopefuls line up after woeful 2011
January 06, 2012
Small caps produce clear winners and losers in 2011
October 04, 2011
Pharmasset continues to lead small cap gainers so far in 2011
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
March 22, 2021
AACR 2021 preview – the early themes emerge
March 24, 2021
Big pharma’s key catalysts in the second quarter
March 03, 2021
A busy year ahead for Parkinson’s disease
March 23, 2021
Frequency refuses to hear the death knell
February 18, 2021
The reckoning begins for biotech-focused Spacs
